Stock Touching New Highs: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Amedica Corporation (NASDAQ:AMDA), China Nepstar Chain Drugstore (NYSE:NPD), Marina Biotech (OTCMKTS:MRNA)


Inovio PharmaceuticalsInovio Pharmaceuticals, Inc. (AMEX:INO) carrying well above the $3.50 level today. It was announced lat week that President and CEO, Dr. J. Joseph Kim, will present a corporate overview of the company at theCowen and Company 34th Annual Health Care Conference in Boston, MA. On last trading day Inovio Pharmaceuticals Inc (NYSEMKT:INO) ended up 15.53% higher to close at $3.72 while trading in the range of $3.38 – $3.95. Its return on assets (ROA) is -84.90% while return on investment (ROI) is -68.30%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) monthly performance is 47.04%.

Amedica, Corporation (NASDAQ:AMDA) which develops and sells medical devices using its silicon nitride technology platform, raised $20 million by offering 3.5 million shares at $5.75, below the range of $8 to $10. Amedica Corporation (NASDAQ:AMDA) in last trading activity ended up at $8.81 with day range of $8.01 – $ 9.37. Company weekly performance is 55.11%. Amedica Corporation (NASDAQ:AMDA) is 11.80% away from its 52 week high.

China Nepstar Chain Drugstore Ltd. (ADR) (NYSE:NPD) is a retail drugstore chain in China. As of December 31, 2012, its store network was comprised of 2,132 directly operated drugstores. The Company provides its customers with professional and convenient pharmacy services and a variety of other merchandise, including over-the-counter (OTC) drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. China Nepstar Chain Drugstore Ltd. (ADR) (NYSE:NPD) belongs to Services sector with market capitalization of 266.55 M. In last trading activity company’s stock closed at $2.70 while opening price was $2.30.

Marina Biotech Inc (OTCMKTS:MRNA) announced entering into a binding term sheet with biotechnology investors led by Steven T. Newby. It will issue convertible preferred stock at an exchange price equivalent to $0.75 a share of common stock which would fetch it $6 million. On Monday shares of Marina Biotech, Inc. (OTCMKTS:MRNA) opened at $1.25 and closed at $1.42. This year Company’s Earnings per Share (EPS) growth is -83.79% and next year’s estimated EPS growth is 48.10%. Analysts mean target price for Marina Biotech, Inc. (OTCMKTS:MRNA) is $20.50. Marina Biotech, Inc. (OTCMKTS:MRNA)